All In Biotech

Drug Trial Radar · NCT05407064

A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms

A Phase 2, Multi-center, Randomized, Double-Blind, Parallel-Group, Dose-Finding Study to Assess the Effect of Four Doses of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms

Last checked: Nov 19, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 198 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

198

Actual

Start

Aug 24, 2022

Primary completion

Oct 6, 2023

Study completion Nov 27, 2023

Sponsor

Lead sponsor
Definium Therapeutics US, Inc.Industry
Sponsor type
Industry
First posted
Jun 7, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, multi-center, randomized, double-blind, parallel-group, dose-finding study to assess the effect of 4 doses of MM120 (25, 50, 100 or 200 μg freebase-equivalent) for the treatment of anxiety symptoms in subjects diagnosed with generalized anxiety disorder (GAD).

Conditions

  • Anxiety Generalized

Interventions

  • MM120Drug

    A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).

  • PlaceboOther

    A substance that is designed to have no therapeutic value.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose ResponseTime frame: 4 weeks

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • Preferred Research Partners

    Little Rock, Arkansas

  • Irvine Center for Clinical Research

    Irvine, California

  • Kadima Neuropsychiatry Institute

    La Jolla, California

  • Pacific Neuroscience Institute

    Santa Monica, California

  • Mountain View Clinical Research

    Denver, Colorado

  • Wholeness Center

    Fort Collins, Colorado

  • Segal Trials

    Lauderhill, Florida

  • CNS Healthcare - Orlando

    Orlando, Florida

  • iResearch Atlanta

    Decatur, Georgia

  • Great Lakes Clinical Trials

    Chicago, Illinois

  • Uptown Research

    Chicago, Illinois

  • Sunstone Therapies

    Rockville, Maryland

  • SISU

    Springfield, Massachusetts

  • Adams Clinical

    Watertown, Massachusetts

  • Hassman Research Institute

    Berlin, New Jersey

  • GMI - Princeton Medical Institute

    Princeton, New Jersey

  • Lutheran Hospital - Cleveland Clinic

    Cleveland, Ohio

  • BioBehavioral Research of Austin

    Austin, Texas

  • University of Texas Health Houston

    Houston, Texas

  • Cedar Clinical Research

    Draper, Utah

  • Cedar Clinical Research - Murray

    Murray, Utah

  • Woodstock Research Center

    Woodstock, Vermont

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.